Posted by Michael Wonder on 03 Sep 2016
EMA publishes EPAR for Cinqaero (reslizumab)
2 September 2016 - The EMA has published an EPAR for Teva Pharmaceuticals' Cinqaero.
The European Commission approved Cinqaero on 16 August 2016 for use as add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.
